Probe intensifies spotlight on AstraZeneca in China: Global pharmas and local biotechs weigh fallout of investigation into AZ China head
About us
BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. When you subscribe to BioCentury, our team of Ph.D.s, analysts and industry experts become an extension of your team, helping you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. We also help you to build your network by connecting you the who’s who in the industry. Watch the latest episodes of The BioCentury Show on YouTube www.biocenturyyoutube.com Subscribe to the "BioCentury This Week" podcast www.biocenturypodcast.com
- Website
-
http://www.biocentury.com
External link for BioCentury Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Redwood City, CA
- Type
- Privately Held
- Specialties
- Biotechnology, Pharmaceutical, Healthcare Ecosystem, Drug Development, Business Strategy, Policy, Regulatory, Finance, Deal Making, Venture Capital, and biopharma
Locations
-
Primary
Get directions
Redwood City, CA 94065, US
Employees at BioCentury Inc.
Updates
-
Myths and misperceptions. What are biotechs, pharmas and academics getting wrong about each other?
Myths and misperceptions — industry’s stumbling blocks
biocentury.com
-
What separates successful investors from those who fall behind? The ability to identify opportunities before they become obvious. At our upcoming virtual Drug Development Disco, Joel Sandler, Ph.D., Nicholas Mitchell, Ph.D. and Matt Krebs dive deep into how you can refine your discovery process, spot the unseen, and turn insights into investments.
Drug Development Disco
www.linkedin.com
-
.@EliLillyandCo discontinued PD-1 agonist peresolimab last week, but was the target the problem? @AnaptysBio and Santa Ana Bio are making the case for optimized agonistic antibody designs that could more effectively repurpose the cancer target for inflammatory diseases.
Are PD-1 agonists finally on the verge of impacting inflammation?
biocentury.com
-
Thank you to everyone that joined us for the 11th #BioCenturyChinaSummit in Shanghai! While in-person sessions have ended, you can still register for a digital pass to access live recordings of the sessions and schedule virtual partnering meetings with delegates (Nov. 5-6). Learn more: https://lnkd.in/gTiC3vY2
-
-
-
-
-
+1
-
-
The BayHelix Woman Leader of the Year award goes to Dr. Michelle Yu Xia - Founder, Chairwoman, President & CEO of Akeso Biopharma! As the founder of one China’s fastest-rising biotechs, Dr. Xia had a banner year in 2024, with Akeso’s bispecific ivonescimab beating Merck’s Keytruda in a China Phase 3 study in NSCLC. On behalf of the BioCentury-BayHelix China Healthcare Summit, congratulations! View all winners: https://lnkd.in/gjrr6ukJ The BayHelix Group #BioCenturyChinaSummit #biotech #lifesciences #investor #biopharma #venturecapital #drugdevelopment #businessdevelopment
-
-
The BayHelix Company of the Year award goes to Legend Biotech! Founded in 2014, Legend had a landmark year in 2024, propelled by a second-line approval for multiple myeloma for its CAR T product Carvykti. The product, partnered with J&J, continues to widen the sales gap over Bristol Myers Squibb's competing CAR T, Abecma. On behalf of the BioCentury-BayHelix China Healthcare Summit, congratulations! View all winners: https://lnkd.in/gjrr6ukJ The BayHelix Group #BioCenturyChinaSummit #biotech #lifesciences #investor #biopharma #venturecapital #drugdevelopment #businessdevelopment
-
-
The BayHelix Commercial Achievement of the Year award goes to XtalPi Inc.! The company’s AI and robotics-enabled drug discovery solutions business saw rapid growth in 2024, helping to drive investor interest as it became the first company to list under HKEX’s 18C rules, raising roughly HK$1B. On behalf of the BioCentury-BayHelix China Healthcare Summit, congratulations! View all winners: https://lnkd.in/gjrr6ukJ The BayHelix Group #BioCenturyChinaSummit #biotech #lifesciences #investor #biopharma #venturecapital #drugdevelopment #businessdevelopment
-
-
The BayHelix R&D Achievement of the Year award goes to Akeso Biopharma! In September 2024, Akeso announced results from a China Phase 3 study of ivonescimab, a VEGFxPD-1 bispecific antibody. In a head-to-head trial in first-line NSCLC, the drug nearly doubled progression-free survival over Keytruda. On behalf of the BioCentury-BayHelix China Healthcare Summit, congratulations! View all winners: https://lnkd.in/gjrr6ukJ The BayHelix Group #BioCenturyChinaSummit #biotech #lifesciences #investor #biopharma #venturecapital #drugdevelopment #businessdevelopment
-
-
The BayHelix Deal of the Year award goes to both Gracell Biotechnologies and PROTEOLOGIX Inc! ➤ Founded in 2017 by Dr. Wei William Cao, China cell therapy play Gracell was acquired in December 2023 by AstraZeneca for $1B up front and $200M in contingent value rights. If CVRs are achieved, it would represent an 86% premium to Gracell's closing market price. ➤ Founded in 2021, Proteologix, a three-year old private biotech, was acquired by J&J in May 2024 for $800M in cash with the potential for an additional milestone payment. The company focuses on bispecific antibodies for immune-mediated diseases with a lead product about to enter Phase 1 trials for atopic dermatitis. On behalf of the BioCentury-BayHelix China Healthcare Summit, congratulations! View all winners: https://lnkd.in/gjrr6ukJ The BayHelix Group #BioCenturyChinaSummit #biotech #lifesciences #investor #biopharma #venturecapital #drugdevelopment #businessdevelopment
-